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survival. The primary objective of this review was to examine the effect of levosimendan use on VA-ECMO weaning and mortality in critically
ill patients on VA-ECMO.
Design: MEDLINE, EMBASE, and CENTRAL were searched. A pair of reviewers identified eligible clinical trials. Two reviewers extracted
data and independently assessed the risk of bias. A random-effect model was used to combine data. The primary outcome was the success of
weaning from VA-ECMO.
Measurements and Main Results: Seven studies of observational design, including a total of 630 patients, were selected in the final analysis. The
sample size ranged from ten-to-240 patients, with a mean age between 53 and 65 years, and more than half of them underwent cardiac surgeries.
The VA-ECMO durations varied between four and 11.6 days. Overall, levosimendan use was significantly associated with successful weaning
compared with control (odds ratio [OR] 2.89, 95% CI, 1.53-5.46; poverall effect = 0.001); I
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2 R. Kaddoura et al. / Journal of Cardiothoracic and Vascular Anesthesia 00 (2021) 113included in the meta-analysis involving 326 patients in the levosimendan group and 291 in the comparator group. Pooled results showed a signif-
icantly higher survival rate in the levosimendan group (OR0.46, 95% CI, 0.30-0.71; poverall effect = 0.0004; I
2 = 20%).
Conclusions: Levosimendan therapy was significantly associated with successful weaning and survival benefit in patients with cardiogenic or
postcardiotomy shock needing VA-ECMO support for severe cardiocirculatory compromise. To date, there is limited literature and absence of
evidence from randomized trials addressing the use of levosimendan in VA-ECMO weaning. This study may be considered a hypothesis-generat-
ing research for randomized controlled trials to confirm its findings.
 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/)
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agement of cardiogenic shock, the rates of morbidity and mor-
tality still are very high.1 Inadequate tissue perfusion
characterizes cardiogenic shock of any etiology, resulting in
global ischemia and imminent multiorgan failure.2 During the
last two decades, mechanical circulatory support devices,
especially veno-arterial extracorporeal membrane oxygenation
(VA-ECMO), emerged as a temporary support system for
patients with cardiogenic shock refractory to conventional
pharmacologic therapy, which allows time for potential car-
diac recovery.3 VA-ECMO increases mean arterial blood pres-
sure and oxygen delivery, thereby improving tissue perfusion
and gas exchange.4 On the other hand, prolonged use of VA-
ECMO can lead to serious complications such as bleeding,
thromboembolic complications, acute brain or lung injury, and
limb ischemia. However, weaning from VA-ECMO is chal-
lenging, and can be a prolonged process that may last for days
or sometimes weeks.5 VA-ECMO weaning usually is facili-
tated by the use of beta-adrenergic agonists, such as dobut-
amine, dopamine, and epinephrine, or phosphodiesterase
inhibitors, such as milrinone and enoximone.6 Prolonged use
of beta-adrenergic agonists may cause tachyarrhythmias and
myocardial ischemia,7,8 increase myocardial oxygen demand,
and impair myocardial relaxation that leads to increasing left
ventricular (LV) myocardial strain.6 Moreover, the undesirable
effect on the overall outcome as a result of metabolic acidosis
and vasoconstriction impairs the microcirculation and triggers
a systemic inflammatory response.9 Phosphodiesterase inhibi-
tors may have some advantages over the catecholamines in
facilitating VA-ECMO weaning, as they augment myocardial
contractility through increasing intracellular calcium levels,
reducing afterload, and decreasing LV strain. However, this is
at the expense of increased myocardial oxygen consumption.
Consequently, the risk of arrhythmias and cardiotoxicity
remains an issue.6 Although the pharmacologic support in
VA-ECMO weaning is limited to beta-adrenergic agonists and
phosphodiesterase inhibitors, the calcium-sensitizing inotropic
agent levosimendan is gaining popularity.
Levosimendan is a novel, first-in-class calcium sensitizer,
currently available in several countries in Europe and beyond,
but has not yet been approved in the United States. Levosimen-
dan enhances myocardial contractility by amplifying calcium
sensitivity of cardiac myocytes, without increasing the intra-
cellular calcium.6,10 It increases cardiac output and strokevolume and reduces peripheral vascular resistance11 without
increasing myocardial oxygen consumption; thus, there is no
increased risk of serious arrhythmogenic effects.6,10,11 Further-
more, it has a long therapeutic effect that may last for weeks,
due to the long half-life of one of its active metabolites (eg,
OR-1896, OR-1855).5,10 OR-1896 probably is the clinically
relevant metabolite.10 Additionally, levosimendan possesses
anti-inflammatory and cardioprotective effects11 and has been
used successfully in patients with postcardiotomy myocardial
dysfunction.6,11 Potassium adenosine triphosphate channels,
which are present in systemic, pulmonary, and coronary vascu-
lar smooth muscles, also are activated by levosimendan. The
resultant smooth muscle relaxation improves coronary per-
fusion and decreases systemic and pulmonary vascular
resistances; thus, unloading both ventricles. Theoretically,
these pharmacodynamic properties may enhance myocar-
dial recovery and facilitate VA-ECMO weaning.6 Although
the current evidence has suggested favorable effects of lev-
osimendan on VA-ECMO weaning and survival in patients
with cardiogenic shock after acute myocardial infarct, acute
myocarditis, and after cardiac surgery, these findings have
not been confirmed in large trials.12 The objective of this
study was to evaluate the effectiveness of levosimendan on
VA-EMCO weaning and mortality in critically ill adult
patients on VA-ECMO.
Methods
This systematic review and meta-analysis were conducted in
compliance with the recommendations of the “Cochrane
Handbook for Systematic Reviews,”13 and reported according
to the Preferred Reporting Items for Systematic Reviews and
Meta-analyses (PRISMA) statement14-16 and the Meta-analysis
Of Observational Studies in Epidemiology (MOOSE)17 check-
list. The review protocol was published in the International
Prospective Register of Systematic Reviews (PROSPERO
2019 CRD42019137208).18
Eligibility Criteria
All studies that used levosimendan for VA-ECMO weaning
in critically ill adult subjects were included. Parenterally
administered levosimendan as the intervention group was con-
sidered without any restrictions in terms of dose or duration of
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control such as placebo, other inotropes, or no intervention.
Search Strategy
An electronic literature search was conducted on June 1,
2019, by two authors (R.K., M.I.) using MEDLINE,
EMBASE, CENTRAL, Scopus, ScienceDirect, ProQuest Pub-
lic Health, and Web of Science. Boolean terms “OR” and
“AND,” Medical Subject Headings (MeSH), Emtree, and
broad key words were used. The search terms included
“simendan,” “levosimendan,” “extracorporeal membrane oxy-
genation,” “ECMO,” “extracorporeal life support,” “ECLS,”
“mechanical circulatory support,” and “MCS.” Search limita-
tions were not applied. The literature search was updated on
June 30, 2020, using MEDLINE, EMBASE, and CENTRAL,
with the aforementioned terms. Additionally, unpublished
studies were sought through US National Institutes of Health
Registry (clinicaltrials.gov), ISRCTNregistry, and OpenGrey.
The reference lists of the retrieved articles and other system-
atic reviews were manually screened. The detailed search strat-
egy is described in Table S1.
Study Selection and Data Extraction
All titles and abstracts were reviewed. Irrelevant studies,
duplicate publications, and nonadult studies were excluded.
All potentially relevant abstracts were retrieved in full text and
reviewed in duplicate to determine the final reports. The
included studies were tabulated, and their data were extracted
for the study objective(s), design, duration, sample size, crite-
ria of inclusion and exclusion, interventions, comparators, rel-
evant definitions, indication and duration of VA-ECMO,
outcomes, results, limitations, and conclusions. A template of
the data extraction tables is included in Table S2. The corre-
sponding authors of the included studies were contacted for
missing or additional details. The primary outcome was wean-
ing from VA-ECMO. Weaning was defined according to each
study. The secondary outcomes included mortality and any
other relevant outcomes such as length of stay (intensive care
unit [ICU], hospital), use of vasopressors, improvement in
hemodynamic or echocardiographic parameters, and safety
outcomes. According to data availability, a time-specific anal-
ysis of mortality (short- and/or long-term mortality) was con-
ducted. The Grading of Recommendations Assessment,
Development, and Evaluation (GRADE) system was used to
assess the quality of evidence of the main outcomes.19-26 The
certainty in the body of evidence for each outcome was rated
as high, moderate, low, or very low. The assessment included
judgments about imprecision, risk of bias, indirectness, incon-
sistency, and publication bias.
Risk of Bias Assessment
The validity of the observational studies was evaluated
using the Risk Of Bias In Non-randomized Studies of Interven-
tions (ROBINS-I) risk of bias tool.27,28 ROBINS-I toolassesses seven domains, and, accordingly, the level of bias
was classified as low, moderate, serious, critical risk, or no
information. The Cohen kappa coefficient29 was used to mea-
sure the agreement on risk of bias (RoB) assessment of the
included studies between two authors. Any disagreement was
discussed until a consensus was reached.
Statistical Analysis
The odds ratios (OR) with 95% confidence intervals (CI)
were calculated. The number-needed-to-treat (NNT) was cal-
culated for the statistically significant pooled outcome results.
Data were combined in systematic review, forest plots, and
meta-analysis. Two studies were set as the minimum number
for quantitative synthesis of data in a meta-analysis for each
study outcome.30 The meta-analysis was carried out using an
aggregate data approach. In the initial stage, both of the indi-
vidual study statistics and combinations of them were carried
out. Then, the random-effects model was used. The analysis
included the study of potential covariates, overall effect size,
and the existence of heterogeneity. Inconsistency among stud-
ies was assessed by visual inspection of forest plots, CI and its
minimal or no overlap, the Q statistic, and the inconsistency
factor (I2) value. I2 values 50% were considered highly het-
erogeneous. The following thresholds have been suggested as
a rough guide: 0% to 40%: might not be important; 30% to
60%: may represent moderate heterogeneity; 50% to 90%:
may represent substantial heterogeneity; and 75% to 100%:
considerable heterogeneity.31 The sensitivity analysis was
explored for the dichotomous outcome measures. Studies were
removed and included based on sample size or methodologic
issue to check if the overall result, that is, OR and conclusions,
were not affected. Sensitivity analysis involves undertaking
the meta-analysis twice: first by including all studies and then
by excluding studies and looking at the overall effect; that is,
to check if the overall result and conclusions were not affected.
The sensitivity analysis explored the impact of excluding or
including studies in a meta-analysis based on sample size,
methodologic quality, or variance.32,33 The potential for publi-
cation or reporting bias was examined by visual inspection of
the funnel plots. Review Manager Software 5 (Review Man-
ager [RevMan] Version 5.3.) and SPSS version 26 (IBM Corp,
Armonk, NY) were used for each analysis.
Results
The literature search (Fig 1) resulted in a total of 1,094
records that were screened. After eliminating duplicates and
studies that did not meet the inclusion criteria, 26 full-text
articles were assessed for eligibility. Twenty studies were
excluded (Table S3) and seven34-40 (Table 1) involving 630
patients were included in the analyses. One case report41 was
found to be relevant (Table S4). Four corresponding authors
were contacted for missing data; two of them responded and
only one35 provided additional data. The search of the US
National Institutes of Health Registry using “levosimendan” as
a broad term resulted in 72 studies. Two registered
Fig 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses
flow diagram—study selection and exclusion.
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updated literature search resulted in 122 studies. Three data-
bases were used: PubMed (17 studies), EMBASE (101 stud-
ies), and CENTRAL (four studies). There were 79 duplicatesTable 1
Study General Characteristics
First Author Year Country Number of Patients Study Site
Affronti34 2013 Italy 17 Single center
Distelmaier35 2016 Austria 240 Single center O
Haffner36
(poster)
2018 France 63 Single center
Jacky37 2018 Switzerland 64 Single center Observ
Sangalli38 2016 Italy 10 Single center Obser
Vally39 2019 France 150 Single center O
Zipfel40
(poster)
2018 Germany 86 Single center
Table 2
Registered Clinical Trials
Trial Identifier* Title (Acronym) Agent (s) Design (Phase

















* From http://clinicaltrials.gov. Accessed July 15, 2020.and 30 studies that did not meet the inclusion criteria. The
remaining 13 studies also were excluded (Table S3).
The seven single-center studies used observational design.
Five of them were published as full articles34,35,37-39 and the
remaining two as posters36,40 with sufficient information. The
studies were conducted in Europe between 2013 and 2019,
with study periods ranging from one-to-11 years. The sample
size ranged from ten-to-240 patients with a mean age range of
53-to-65 years. The largest study35 (n = 240) accounted for
approximately 40% of the patients in this review. Half of the
patients (n = 304) from two studies35,37 were patients after car-
diac surgery. The remaining studies34,36,38-40 enrolled surgical
and nonsurgical patients (Table 3).
The VA-ECMO duration ranged from four days to
11.6 days. Weaning protocol was not stated in three
studies.35,36,40 Two studies35,39 defined weaning failure as
death during VA-ECMO support or death 24 hours after VA-
ECMO removal. One study37 defined successful weaning as
24-hour survival afterVA-ECMO removal without the need
for repeat VA-ECMO. All the studies except two36,40 stated
levosimendan dosing regimen with an almost similar
approach; that is, without loading dose, within the usual rate
range, and for 24 hours. Timing of levosimendan initiation
varied among studies; that is, pretreatment before wean-
ing,34,38 after VA-ECMO initiation35 or cannulation,39 or dur-
ing weaning.37 Traditional inotropes and vasopressors wereStudy Design Recruitment Period Study Duration
Before-after design; case series January to December 2011
(1 y)
bservational retrospective registry September 2003 to June 2014
(11 y)
Observational retrospective 2014 to 2016
(2 y)
ational retrospective; before-after design 2007 to 2013
(6 y)
vational prospective, before-after design Not mentioned
(before 2016)
bservational retrospective cohort January 2010 to March 2017
(7 y)
Observational retrospective January 2013 to December 2016
(4 y)
) Enrollment Primary Outcome Start Date Status




206 ECLS withdrawal failure December 2019 Not yet
recruiting
Table 3


















▪ Pre-ECMO LVEF (16%)
▪ CrCl: 113 mL/min (group A) vs
52 mL/min (group B)
▪ Etiology of CS: AMI (48%), acute myo-
carditis (30%), and postcardiotomy
(22%)
▪ IABP use: 100%
▪ Patients were on at least 2 high-dose
inotropes
▪ Cardiopulmonary failure not
responding to pharmacologic and
IABP support but potentially
reversible (ELSO criteria)
▪ Median 8-9 d (NS between
groups)
Flow:
▪ Reducing pump flow by 0.5 L/h (usually
accomplished within 48 h)
Routine monitoring:
▪ ECHO
▪ Swan-Ganz catheter: hemodynamic
status





▪ ICU ▪ Inclusion: VA-ECMO
support after CV surgery
▪ Exclusion: age <18 y
▪ 65 y
▪ 71%
▪ CAD (50%), HTN (70%), DM (25%)
▪ IABP use: not stated
▪ Median SAPS-3 = 43, median Euro-
SCORE = 10 (both are significantly dif-
ferent between groups; higher in
levosimendan group)
▪ Severely reduced LV function (35%)
(significantly different between groups;
sicker in levosimendan group)
▪ Clinical signs of severe CS (eg,
SBP <80 mmHg), and signs of
end-organ failure, anaerobic
metabolism, and metabolic acido-
sis despite optimized supportive
measures (ie, inotropes, fluids,
and IABP)
▪ Weaning failure from cardiopul-
monary bypass (60%), post-op CS
(20%), immediate post-transplant
cardiac graft failure (6%), post-op
respiratory failure (4%), post-op
bleeding or tamponade with CS
(4%), and others (6%)
▪ Median 4 d
▪ Not stated
▪ Weaning failure defined as death during





▪ ICU ▪ Inclusion: primary CS or
postcardiotomy on AV-
ECMO
▪ Exclusion: death under






▪ IABP use: not stated
▪ CS or postcardiotomy
















▪ CAD (69%), HTN (64%), DM (23%), HF
(25%), renal dysfunction (33%), lung dis-
ease (19%), valve disease (47%), CM
(14%), CHD (31%), PAD (14%), mean
SAPS II (51), smokers (59%)
▪ IABP use: 26.5%
▪ Sicker patients on levosimendan, ie, more
sepsis and liver impairment
▪ As per multidisciplinary decision
▪ Duration not reported
▪ Weaning starts when patient is stable dur-
ing at least 48 h
▪ ECLS flow was reduced in steps of 0.5 to
2.5 L/min under minimal inotropic
support
▪ After specified monitoring, ECLS flow
was reduced in steps of 0.5 L/min. After
3 h of hemodynamic stability at 1 L/min,
ECLS was removed
▪ Successful weaning defined as 24-h sur-
vival after removal of ECLS without a
need for re-ECLS















































































CS due to AMI and LVEF
<25%




▪ HTN (50%), DM (40%), smokers (40%),
alcohol (20%), mean SAPS II (54.4)
▪ IABP use: not stated
▪ Refractory CS due to AMI with
LVEF <25%
▪ 11.5 d
▪ Stepwise reduction of pump flow (0.5 L
every 6-24 h), if inotropic score was 10






▪ Inclusion: ICU patients on
VA-ECMO
▪ Exclusion: age <18 y,
VA-ECMO duration <2




▪ CAD (29%), HTN (43%), DM (36%),
congestive HF (23%), CKD-HD (10%),
COPD (5.3%), smokers (31%), alcohol
(20%), mean SAPS II (59.2), mean GCS
(12.7), mechanical ventilator (91%), RRT
(40%)
▪ IABP use: 28%
▪ More patients on levosimendan had




▪ Reasons varied between groups
(p = 0.024)
▪ 11.6 d
▪ VA-ECMO flow gradually decreased to
1-1.5 L/min
▪ VA-ECMO was removed when: MAP
>65 mmHg; low doses of catecholamine;
PaO2/ FiO2 ratio >100 mmHg; LVEF
>20%; and aortic velocitytime integral
>12 cm
▪ Weaning failure defined as death during












▪ IABP use: not stated
▪ Any indication for VA-ECLS
▪ 182 h vs 216 h (p = 0.21)
▪ Not stated
Abbreviations: ABG, arterial blood gas; AMI, acute myocardial infarction; BNP, brain natriuretic peptide; CAD, coronary artery disease; ECHO, echocardiographic; CHD, congestive heart disease; CKD-HD,
chronic kidney disease with hemodialysis; CM, cardiomyopathy; COPD, chronic obstructive pulmonary disease; CrCl, ceatinine clearance; CS, cardiogenic shock; CT, cardiothoracic; CV, cardiovascular; DM,
diabetes mellitus; ECMO, extracorporeal membrane oxygenation; ECLS, extracorporeal life support; ELSO, Extracorporeal Life Support Organization; h, hour; ICU, intensive care unit; GCS, Glasgow Coma Scale
score; HF, heart failure; HTN, hypertension; IABP, intra-aortic balloon pump; LV, left ventricular; LVEF, left ventricular ejection fraction; NS, not significant; OR, operating room; PAD, peripheral artery disease;
RRT, renal replacement therapy; SAPS, simplified acute physiology score; SBP, systolic blood pressure; VA, veno-arterial; VV, veno-venous.













































































1. Levosimendan: infused for 24 h
before planned weaning at 0.005 then
increased up to 0.2 mg/kg/min within
1-2 h (no loading)
2. Traditional inotropes or vasopressors
1. Weaning rate: 83.3% vs 27.3%
(p = 0.0498)
1. In-hospital: 33.3% vs 63.4% (NS) 1. ICU: median 18.5 vs
19 days (NS)
2. Hospital: median
28.5 vs 30 d (NS)
1. Inotropic or vasopressor support:
50% vs 100% (p = 0.00294)





1. Levosimendan: 12.5 mg in 50 mL of
0.9% NaCl infusion (no bolus) within
the first 24 h after initiation of ECMO
2. Traditional inotropes and vasopres-
sors as per weaning strategy
1. Weaning failure: 19.5%
vs 33.8%*
2. adj HR = 0.41 (95% CI,
0.22-0.80; p = 0.008)
3. Weaning failure: occurred in 23%
of patients (overall)
1. 30-d: 62% vs 74%*
2. adj HR = 0.52 (95% CI, 0.30-
0.89; p = 0.016)
3. long-term: adj. HR = 0.64 (95%
CI, 0.42-0.987; p = 0.04)
- ▪ Inotropic or vasopressor support
24 h post-ECMO: significantly





▪ Levosimendan: dose not stated
▪ Comparator: control-no
levosimendan
▪ Weaning failure: 24%
vs 20% (Pr = 0.34)
Postcardiotomy sub-group:
▪ Weaning failure: 12% vs 29%
(Pr = 0.9); OR = 0.073 (Pr = 0.92)
▪ Mortality: 34% vs 36% (Pr = 0.6) - ▪ Higher assistance duration, longer
stay under mechanical ventilation,





▪ Levosimendan: started at rate 0.1 mg/
kg/h (no bolus)
▪ Comparator: milrinone at rate 10 mg/
min (range 5-20mg/min)
▪ Both started during ECLS weaning
▪ Successful weaning: 92% vs 79%
(p = 0.18)
▪ 28-d mortality: 35% vs 40%
(p = 0.28)
▪ 180-d mortality: 50% vs 44%
(p = 0.80)
▪ ICU: 27 vs 17 d
(p = 0.017)
▪ Hospital: 33 vs 22 d
(p = 0.038)
▪ IABP use during weaning: 7.7%
vs 40% (p = 0.008)
▪ Catecholamine use: no difference
in NE use but in epinephrine’s, ie,





▪ Levosimendan: started at rate 0.1
mcg/Kg/min (no loading). Infusion
was interrupted after 24 h, then wean-
ing test was attempted
▪ Comparator: none
▪ Successful weaning: in 90% of
patients
▪ ECMO blood flow reduced from
1.92 to 1.12 L/min/m2 (p <
0.001)
▪ One patient died immediately
after decannulation
▪ ICU survival rate: 80% (another
patient died from septic shock
while still in ICU 38 d after dec-
annulation)
- ▪ Cardiac index increased from
1.93 to 2.64 L/min/m2 (p = 0.008)
▪ Mixed venous oxygen saturation
increased from 66.0% to 71.5%
(p = 0.006)
▪ Arterial lactate decreased from
1.25 to 1.05 mmol/L (p = 0.004)
▪ FMD (absolute value): increased
from 0.10 to 0.61 mm (p< 0.001)
▪ FMD (%): increased from 3.2% to
17.8% (p < 0.001)
▪ Peak blood flow increased from




▪ Levosimendan: 12.5 mg in 100 mL of
0.9% NaCl at rate 0.2 mg/kg/min (no
bolus) for 24 h
▪ Administered after 3.2 d after ECMO
cannulation
▪ Comparator: not specific; catechol-
amines § IABP at physician’s
discretion
▪ Weaning: 82.4% vs 61.6%
(p = 0.01)
▪ HR = 0.16 (0.04-0.7); p = 0.01
(after propensity matching)
▪ Survival rate: 78.4% vs 49.5%
(p = 0.02)
▪ 30-d mortality, HR = 0.55 (0.27-
1.1); p = 0.09 (after propensity
matching)
- In levosimendan groups:
▪ LVEF increased from 21.5 to
30.7% (p < 0.0001)
▪ Aortic velocitytime integral





▪ Levosimendan: no details
▪ Comparator: not stated
▪ 64.8% vs 32.6% (p = 0.003) ▪ In-hospital survival: 51.3% vs
23.4% (p = 0.005)
- -
Abbreviations: Adj, adjusted; CI, confidence interval; ECMO, extracorporeal membrane oxygenation; ECLS, extracorporeal life support; FMD, flow-mediated dilatation; HR, hazard ratio; ICU, intensive care unit;
h, hour; NaCl, sodium chloride; NE, norepinephrine; NS, not significant; OR, odds ratio; Pr, probability.
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and none or unspecified in the remaining studies36,38-40
(Tables 3 and 4).
Risk of Bias
All the studies were at risk of bias due to confounding
(Tables S5 and S6), which affected the overall judgment of
bias for the two main outcomes—VA-ECMO weaning and
mortality (Table 5). For VA-ECMO weaning, kappa values for
agreement between the two reviewers ranged between 0.731
and 1.00. Although, for mortality, kappa values ranged from
0.432 to 0.632.Outcomes
VA-ECMO Weaning
VA-ECMO weaning was reported in all studies (n = 630);
336 patients in the levosimendan group and 294 in the compa-
rators group. Successful weaning was found statistically sig-
nificant in four studies.34,35,39,40 Overall, levosimendan use
was significantly associated with successful weaning com-
pared with the control arm (OR 2.89, 95% CI, 1.53-5.46; pover-
all effect = 0.001). The higher the weight the more influence it
has on the overall measure of heterogeneity; I2 = 49%;
p = 0.07) (Fig 2 and Fig S1). The GRADE confidence in this
estimate was very low (Table 6). Sensitivity analysis (Table
S7, Figs S2 and S3) by excluding the 2two studies36,40 at criti-
cal risk of bias showed comparable results (OR 3.64, 95% CI,
1.59-8.33; I2 = 49%).Table 5
Overall Risk of Bias (ROBIN-I)
Domain ECMOWeaning Mortality
Bias due to confounding Critical Critical
Bias in selection of participants into
the study
Serious Serious
Bias in classification of interventions Serious Serious
Bias due to deviations from intended
interventions
Low Low
Bias due to missing data No information No information
Bias in measurement of outcomes Moderate Low




Fig 2. Forest plot—veno-arterial extracorporeaMortality
All the studies reported the occurrences of death. Six studies
(n = 620) were included in the meta-analysis involving 326
patients in the levosimendan group. Pooled results showed a
decreased risk of mortality in the levosimendan group
(OR0.46, 95% CI, 0.30-0.71; poverall effect = 0.0004), without
apparent heterogeneity among the studies (I2 = 20%, p = 0.28)
(Fig 3 and Fig S4). The NNT was five (Table S8). The
GRADE confidence in this estimate was very low (Table 6).
When the two studies36,40 at critical risk of bias were removed
at the same time, the heterogeneity was reduced to 16% and
the results were comparable as well (OR 0.46, 95% CI, 0.28-
0.76; I2 = 16%) (Table S9 and Fig S5).Other Outcomes
Lengths of stays were reported in three studies.34,36,37 Only
one37 of them had significant differences in both ICU and hos-
pital lengths of stay, which were longer in the levosimendan
group (p = 0.017 and p = 0.038, respectively). However, levo-
simendan had favorable effects on other reported hemody-
namic38 and echocardiographic39 parameters. Intra-aortic
balloon pump (IABP) use or need during weaning was signifi-
cantly less in the levosimendan arm37 (p = 0.008) (Table 4).
None of the trials reported adverse drug events.Publication Bias
The funnel plot illustrates the issue of bias and precision. The
funnel plots indicated a reasonable symmetry (Fig. 4 and 5) and a
lack of heterogeneity and publication bias in the meta-analyses.Discussion
This systematic review and meta-analysis of observational
studies examined the effectiveness of levosimendan in VA-
ECMO weaning in ICU patients. The review included seven
studies that compared levosimendan with control, including
traditional vasoactive drugs, milrinone, or none. The included
studies were of small size and enrolled patients from various
settings, with the majority being recruited after cardiac sur-
gery. Pooled data showed that treatment with levosimendan in
patients on VA-ECMO was associated with significant VA-







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































R. Kaddoura et al. / Journal of Cardiothoracic and Vascular Anesthesia 00 (2021) 113 9VA-ECMO is a contemporary life-saving intervention that
allows hemodynamic stability, restores tissue perfusion, and
allows the myocardium to resume its physiologic functions.
However, the challenge after myocardial recovery is weaning
from this device.6 A study suggested that early weaning should
be attempted because both VA-ECMO duration and bleeding
complications were predictors of poor outcomes.42 Moreover,
the pioneer study on the timing of VA-ECMO discontinuation
encouraged weaning from VA-ECMO after 48-to-72 hours
due to the lack of additional benefits afterward.43 In this sys-
tematic review, weaning from VA-ECMO was the primary
outcome of interest as, in the authors’ opinion, it would be
more reflective of the patient’s management course during the
ICU stay. The underlying cause of mortality in ICU patients is
highly alterable and usually is affected by diverse factors.
Thus, surrogate endpoints may be alternative indicators of
treatment effect that may improve its sensitivity.44 In this sys-
tematic review, successful weaning from VA-ECMO and mor-
tality rates were reported in the seven included studies and
ranged from 65% to 92% in the levosimendan group, as com-
pared with 27% to 88% in the comparators group. Likewise,
mortality rates ranged from 20% to 62%, as compared with
36% to 77%, respectively. In a nationwide Japanese study45 on
VA-ECMO patients (n = 5,263), the rate of weaning was
64.4%, with an in-hospital mortality rate of about 65% for all
underlying diseases. However, weaning from VA-ECMO was
not always associated with in-hospital survival. The reported
mortality was 38% for the successively weaned patients.
The use of levosimendan to facilitate weaning was first
reported by Affronti et al., who found that the 24-hour pretreat-
ment with levosimendan before beginning VA-ECMO wean-
ing was associated with successful weaning and reduced need
for inotropic or vasopressor support, but without reducing in-
hospital mortality rate or length of hospital stay.34 Distelmaier
et al. administered levosimendan during the first 24 hours of
VA-ECMO initiation after cardiovascular surgery. Weaning
failure, 30-day mortality, and long-term mortality were signifi-
cantly less. However, the use of inotropes or vasopressors
24 hours after VA-ECMO was significantly more with higher
doses of levosimendan.35 A study conducted by Sangalli et al.
prospectively investigated the effect of levosimendan on endo-
thelial function and hemodynamic parameters in cardiogenic
shock patients. This was the only study in this systematic
review that did not have a comparator group. Levosimendan
was administered for 24 hours before attempting to wean from
VA-ECMO. Successful weaning and survival rate were
reported in 90% and 80% of the patients, respectively, in addi-
tion to the improvements in endothelial function and hemody-
namics.38 The protective effects of levosimendan on
endothelium function and its anti-inflammatory potential prob-
ably are beneficial while using VA-ECMO, which may pro-
voke a proinflammatory effect and endothelial damage.39
Jacky et al. were the first to compare levosimendan use during
VA-ECMO weaning with a specific inotrope, milrinone, in a
historic group of patients after cardiac surgery. The study
showed significant benefit of levosimendan in terms of less
IABP use during weaning, but without significant effects on
Fig 3. Forest plot—mortality.
Fig 4. Funnel plot—veno-arterial extracorporeal membrane oxygenation
weaning success.
Fig 5. Funnel plot—mortality.
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simendan had longer ICU and hospital lengths of stay. How-
ever, there were more patients with sepsis and liver failure.37
Recently, Vally et al. conducted a study in which levosimen-
dan was administered within 3.2 § 2.8 days after VA-ECMO
cannulation and included surgical and nonsurgical patients.
The inotropes in both arms were administered at the phys-
icians’ discretion. Levosimendan had a beneficial effect on
weaning but not on mortality after propensity score matching,
which may be attributed to the lack of study power.39
Silvestri et al. published a poster for a meta-analysis of four
studies34,35,37,39 (n = 471) in August 2019, and suggested that
levosimendan use improves weaning success in cardiogenic
shock. They reported a success rate of 82% versus 65% (OR
1.27, CI, 95% 1.13-1.4; p < 0.01, I2 = 26%) as compared with
the control group.46 While writing the manuscript of this sys-
tematic review, Burgos et al. published their systematic review
and meta-analysis (n = 557)47 to answer a similar question.They included all the studies selected in this systematic review
except two recent studies.36,38 To the best of the authors’
knowledge, these two meta-analyses were the first full
reports that pooled data to investigate the effectiveness of
levosimendan in VA-ECMO weaning. Prior meta-analyses
examined the efficacy and/or safety of levosimendan use in
various medical settings and conditions, such as low-
cardiac-output syndrome,12 acute heart failure,48 cardiac
surgery,49-51 cardiogenic shock,52 and coronary revasculari-
zation.53 Levosimendan, in this systematic review and the
recent one,47 was associated with successful VA-ECMO
weaning (OR 2.89, 95% CI, 1.53-5.46; poverall effect = 0.001,
I2 = 49%) and (risk ratio [RR] 1.42, 95% CI, 1.12-1.8; pfor
effect = 0.004, I
2 = 71%, respectively) and much lower risk
of mortality (OR 0.46, 95% CI, 0.30-0.71; poverall effect =
0.0004, I2 = 20%) and (RR 0.62, 95% CI, 0.44-0.88; pfor
effect = 0.007, I
2 = 36%, respectively). Furthermore, levosi-
mendan improved hemodynamic and echocardiographic
parameters. Due to the suspicion of bias, that is, methodo-
logicissue and dubious eligibility, the two posters36,40 were
excluded from the second meta-analysis of this study,
resulting in improved overall effects for both VA-ECMO
weaning and mortality. This systematic review presented
other important surrogate endpoints. However, pooling
their data was not feasible.
The authors of this review and Burgos et al. have evaluated
the RoB using different assessment tools ie, ROBIN-I tool27,28
and Newcastle-Ottawa scale (NOS), respectively.54 In this sys-
tematic review, the RoB assessment of the included studies
ranged from moderate to critical for both VA-ECMO weaning
and mortality (Tables S5 and S6). The overall RoB was rated
as critical for both outcomes due to the critical bias of con-
founding (Table 5). Burgos et al. assessed the methodologic
strength of the studies using the NOS. They developed a “star
system” to rate each study on three broad perspectives. The
studies’ quality ranged from 6six-to-nine stars, with nine stars
representing the highest level and six stars representing high
quality.47 It is not surprising to reach an opposite conclusion,
which is explained by using tools with different approaches
for RoB assessment. The disagreement is more overt specifi-
cally when at low and high levels of RoB, as was shown in one
study that compared the performance of different tools in 28
cohort studies.55 The frequently used NOS54 is a composite
scoring scale that assesses the quality of cohort and case-con-
trol studies. The Cochrane-proposed ROBIN-I27,28 is a
domain-based tool to assess RoB in nonrandomized studies of
interventions and a wide variety of observational designs. The
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study55 did not show a good correlation for overall RoB.
Although 86% of the studies can be considered at serious RoB
according to ROBINS-I, 75% of the studies would be at low
RoB when the NOS was applied. Both tools differ in most
aspects of usability such as scoring time, coverage of the tool,
loss of information, and ease of consensus. For example, NOS
requires shorter scoring time, which may explain its common
use, although ROBIN-I is more demanding about the informa-
tion and the details needed to be assessed. In addition, it has a
broader scope, which means a more comprehensive analysis of
the studies as compared with NOS. The detailed algorithm of
ROBIN-I probably was the reason for its better performance in
the overall RoB judgment as compared with other tools.55
Finally, another study56 concluded that numeric rating scales
could not identify studies at increased risk of bias and may
have led to imprecise estimates of treatment effect. The
domain-based RoB assessment is gaining more popularity
over the use of numeric scales,55 as it provides a more struc-
tured framework for qualitative decision-making on the overall
quality, and for the detection of possible sources of bias within
the studies and the body of evidence under review. This is nec-
essary as the quality of evidence may differ across the reported
outcomes of the same study, with some being more subject to
bias than other outcomes.56 Additionally, in this systematic
review, the certainty in the body of evidence was rated as very
low for both outcomes on the GRADE system (Table 6). The
quality of evidence in a systematic review is essential as it is a
reflection of the extent of confidence that an estimate of effect
is correct.57
This systematic review had some limitations. The observa-
tional aspect of the included studies with their inherent meth-
odologic limitations subjected them to bias and
confounding.58 In a conservative approach, random effect
model was used to reduce the impact of this limitation and the
potential bias in the estimates. Publication and selection biases
affect the small studies, which usually have lower methodo-
logic quality; thus leading to the so-called small-study effects
that cause larger treatment effects, that is, overestimate of the
true effect.57,59 This precludes having definitive conclusions.
Although the funnel plots in this review were almost symmet-
rical, suggesting a low probability of reporting bias, there were
fewer than ten included studies. In addition, this meta-analysis
pooled data of a heterogeneous population, surgical and non-
surgical, into one overall effect estimate. However, data from
the Extracorporeal Life Support Organization (ELSO) registry
showed equal proportions of both patients’ groups, about 50%
each.60 Other heterogeneous aspects included lack of universal
VA-ECMO weaning definition or protocol across the included
studies; improvement of VA-ECMO experience during recent
years; various dosing regimens and timing of administration of
levosimendan; and failure in describing details of inotropes or
IABP use. For example, as previously mentioned, VA-ECMO
weaning outcome was defined in only three studies,35,37,39 two
of them35,39 defining weaning failure as death during VA-
ECMO support or death 24 hours after VA-ECMO removal,
whereas one37 defined successful weaning as 24-hour survivalafter VA-ECMO removal without the need for repeat VA-
ECMO. Thus, the discrimination between mortality on VA-
ECMO and after VA-ECMO weaning was not be conclusive.
Due to the limitations of this systematic review, the results and
conclusions of the analysis must be taken with caution. Well-
designed randomized trials are awaited to support the favor-
able effects of levosimendan in VA-ECMO weaning. Random-
ized trials also are needed to address other aspects of VA-
ECMO weaning, such as optimal dosing and timing of ino-
trope administration. A registered, randomized controlled,
double-blind, multicenter trial (NCT04158674) investigating
weaning failure, but not survival, in patients with severe
chronic heart failure in acute decompensation is under way.Conclusion
Levosimendan may offer a valid option to facilitate success-
ful weaning from VA-ECMO and to lower the risk of mortal-
ity. The currently available evidence suggests the advantages
of levosimendan use in improving endothelial function, hemo-
dynamics, and echocardiographic parameters, especially in the
absence of major adverse effects. However, the results should
be considered to establish a hypothesis for adequately powered
randomized controlled trials to confirm the conclusions of
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